Vinpocetine - instructions for use, dose, side effects, contraindications

ascorbic acid 0.5 mg, sodium disulfite (sodium pyrosulfite) 1 mg, sorbitol (D-sorbitol) 80 mg, tartaric acid 2.6 mg, benzyl alcohol 10 mg, water for injection up to 1 ml.

Description:

Transparent colorless or slightly colored liquid

Pharmacotherapeutic group:Cerebral blood flow improver

ATX: & nbsp

N.06.B.X.18 Vinpocetine

Pharmacodynamics:

Vinpocetine selectively inhibits the potential-dependent sodium channels, causing a dose-dependent decrease in the concentration of calcium ions in the endings of neurons of the striatum. It is believed that a decrease in the current of sodium ions has a neuroprotective effect due to a decrease in excitotoxicity and a weakening of neuronal damage,caused by cerebral ischemia or reperfusion.

Vinpocetine increases the concentration of 3,4-dihydroxyphenylacetic acid

(a metabolite of dopamine) in the nerve endings of the striatum. This action is similar to the pharmacological action of reserpine (reminiscent of the chemical structure vinpocetine), which depletes the supplies of catecholamines in the nerve endings of the brain; which causes side effects from the cardiovascular system and the antipsychotic effect.

It also inhibits phosphodiesterase 1, which leads to an increase in the concentration of intracellular cyclic guanosine monophosphate. This leads to a relaxation of the smooth muscles of the vessels of the brain.

Pharmacokinetics:The therapeutic concentration for parenteral administration in plasma is 10-20 ng / ml, the volume of distribution is 5.3 l / kg. The connection with proteins - 66%, clearance - 66.7 l / h, exceeds the plasma volume of the liver (50 l / h), which indicates extrahepatic metabolism. Penetrates into breast milk (0.25% within 1 hour), through the placental barrier. The half-life is 3.54-6.12 hours. It is excreted by the kidneys and intestines in the ratio of 3: 2.

Indications:Neurology: as a part of complex therapy for various forms of cerebral circulatory insufficiency (ischemic stroke, recovery stage of hemorrhagic stroke, consequences of a stroke, transient ischemic attack, vascular dementia, circulatory failure in the vertebrobasilar basin, cerebrovascular atherosclerosis, posttraumatic and hypertensive encephalopathy).

Ophthalmology: chronic diseases of the vascular membrane and vessels of the retina (including: occlusion of the central artery or vein of the retina)

Perceptive hearing loss, Meniere's disease, idiopathic tinnitus.

Contraindications:Hypersensitivity to the components of the drug, acute phase of hemorrhagic stroke, severe ischemic heart disease, severe heart rhythm disturbances, pregnancy, lactation, age under 18.

Carefully:Severe rhythm disturbances; with hemorrhagic stroke, the introduction is possible only after the subsidence of acute events (usually in 5-7 days).

Pregnancy and lactation:The use of the drug is contraindicated in pregnancy and during breastfeeding

Dosing and Administration:

Intravenously drip (infusion rate should not exceed 80 cap / min).

The initial daily dose is 20 mg (in 0.5-1 L of a 0.9% solution of sodium chloride or solutions containing dextrose). The average daily dose at a body weight of 70 kg is 50 mg. With good tolerability for 2-3 days, the dose is raised to the maximum; 1 mg / kg / day. The course of treatment is 10-14 days.

After achieving the improvement, they switch to taking the drug inside, if the drug is ineffective, the treatment is canceled.

Side effects:

From the cardiovascular system: changes on the ECG (depression of the ST segment, prolongation of the Q-T interval); tachycardia, extragastomy (cause-and-effect relationship not established), lability of blood pressure (more often decrease).

From the nervous system: sleep disturbance (insomnia, increased drowsiness); dizziness, headache, general weakness (may be a manifestation of the underlying disease).

From the digestive system: dryness of the oral mucosa, nausea, heartburn.

Other: skin allergic reactions, increased sweating, skin hyperemia, phlebitis with intravenous administration.

Overdose:

Symptoms: not described.

Treatment is symptomatic.

Interaction:

The solution of vinpocetine is pharmaceutically incompatible with heparin, solutions containing amino acids.

It is possible to intensify the hypotensive effect with simultaneous application with methyldopa (blood pressure control is necessary).

Special instructions:

When introducing solutions of vinpocetine containing sorbitol, in patients with diabetes should monitor blood glucose.

In the case of the initial extension of the Q-T interval, and also with simultaneous use with agents extending the Q-T interval during the treatment with vinpocetine, periodic ECG monitoring

Effect on the ability to drive transp. cf. and fur:Care should be taken when driving vehicles and engaging in other potentially hazardous activities requiring increased attention and speed of psychomotor reactions.

Form release / dosage:Solution for intravenous administration 5 mg / ml

Packaging:

2 ml into the ampoules of the light-protective glass.

For 10 ampoules with instruction for use and a knife for opening ampoules or a scarifier ampullum is placed in a box of cardboard.

5 or 10 ampoules are placed in a contoured cell pack of a polyvinylchloride film or polyethylene terephthalate tape and aluminum foil or paper with a polyethylene coating or without a foil, or without paper.

For 1 or 2 contour packs with instructions for use and a knife for opening ampoules or a scarifier ampullum is placed in a pack of cardboard.

When you pack the ampoules with a break ring or break point, the ampoule opener or ampoule scapper is not put in.

Storage conditions:

In the dark place.

Keep out of the reach of children.

Shelf life:1 year. Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N003781 / 01

Date of registration:17.06.2011

Expiration Date:Unlimited

The owner of the registration certificate:NOVOSIBHIMFARM, OJSC NOVOSIBHIMFARM, OJSC Russia

Manufacturer: & nbsp

NOVOSIBHIMFARM, OJSC Russia

Information update date: & nbsp18.02.2017

Illustrated instructions

Instructions

Vinpocetine (Vinpocetine)